Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Assessment of cognition in early dementia
Silverberg, Nina, Ryan, Laurie, Petersen, Ronald C. , Posner, Holly, Hilsabeck, Robin C. , Rizzo, Albert, Ott, Brian R. , Albert, Marilyn S. , Wagster, Molly V., Schinka, John A., Cullum, C. Munro , Farias, Sarah Tomaszewski , Balota, David A., Budson, Andrew E. , Strutt, Adriana M. , Gollan, Tamar H. , Babcock, Debra, Kramer, Joel H. , Carrillo, María C. , Sperling, Reisa Anne , Snyder, Peter J. , Gallagher, Michela , Raber, Jacob , Possin, Katherine L. , King, Jonathan W. , Kaye, Jeffrey , Rao, Stephen M. , Loewenstein, David , Brandt, Jason , Manly, Jennifer J. , Barnes, Lisa L. , Ganguli, Mary , Litvan, Irene , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 3 | Pages: No page available

10.1016/j.jalz.2011.05.001 | PMID 23559893 Get It

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Kumar, Shaji , Zhang, Mei-Jie , Li, Peigang , Dispenzieri, Angela , Krishnan, Amrita , Wirk, Baldeep , Weiss, Brendan M. , Freytes, César O. , Vogl, Dan T. , Vesole, David H. , Meehan, Kenneth R., Hamadani, Mehdi , Lill, Michael, Majhail, Navneet S. , Wiernik, Peter H. , Nath, Rajneesh , Kamble, Rammurti T., Vij, Ravi , Kyle, Robert A. , Hari, Parameswaran , Milone, Giuseppe , Lonial, Sagar , Maiolino, Ângelo , Lazarus, Hillard M. , Callander, Natalie S. , Gale, Robert Peter , Dispenzieri, Angela , Hamadani, Mehdi , Majhail, Navneet S , Hari, Parameswaran

Mayo Clinic

Blood | June 21, 2011 | Volume: 118 | Issue: 7 | Pages: 1979-1988

10.1182/blood-2011-02-337329 | PMID 21690560 Get It

Abstract Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P < .0001).
Absorbable Versus Nonabsorbable Mesh Repair of Congenital Diaphragmatic Hernias in a Growing Animal Model
Gonzalez, Rodrigo, Hill, Sarah J. , Mattar, Samer G. , Lin, Edward , Ramshaw, Bruce , Smith, C. Daniel , Wulkan, Mark L.

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | May 4, 2011 | Volume: 21 | Issue: 5 | Pages: 449-454

10.1089/lap.2010.0409 | PMID 21542768 Get It

Use of Bioidentical Compounded Hormones for Menopausal Concerns: Cross-Sectional Survey in an Academic Menopause Center
Iftikhar, Salma , Shuster, Lynne T., Johnson, Ruth E. , Jenkins, Sarah M. , Wahner‐Roedler, Dietlind L.

Mayo Clinic

Journal of Women's Health | April 12, 2011 | Volume: 20 | Issue: 4 | Pages: 559-565

10.1089/jwh.2009.1915 | PMID 21486160 Get It

Caveolin-1 and force regulation in porcine airway smooth muscle
Sathish, Venkatachalem , Yang, Binxia , Meuchel, Lucas W., VanOosten, Sarah Kay, Ryu, Alexander J. , Prakash, Y. S. , Ryu, Alexander J. , Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Sathish, Venkatachalem

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 19, 2011 | Volume: 300 | Issue: 6 | Pages: L920-L929

10.1152/ajplung.00322.2010 | PMID 21421751 Get It

Caveolae are specialized membrane microdomains expressing the scaffolding protein caveolin-1. We recently demonstrated the presence of caveolae in human airway smooth muscle (ASM) and the contribution of caveolin-1 to intracellular calcium ([Ca2+]i) regulation. In the present study, we tested the hypothesis that caveolin-1 regulates ASM contractility. We examined the role of caveolins in force regulation of porcine ASM under control conditions as well as TNF-α-induced airway inflammation. In porcine ASM strips, exposure to 10 mM methyl-β-cyclodextrin (CD) or 5 μM of the caveolin-1 specific scaffolding domain inhibitor peptide (CSD) resulted in time-dependent decrease in force responses to 1 μM ACh. Overnight exposure to the cytokine TNF-α (50 ng/ml) accelerated and increased caveolin-1 expression and enhanced force responses to ACh. Suppression of caveolin-1 with small interfering RNA mimicked the effects of CD or CSD. Regarding mechanisms by which caveolae contribute to contractile changes, inhibition of MAP kinase with 10 μM PD98059 did not alter control or TNF-α-induced increases in force responses to ACh. However, inhibiting RhoA with 100 μM fasudil or 10 μM Y27632 resulted in significant decreases in force responses, with lesser effects in TNF-α exposed samples. Furthermore, Ca2+sensitivity for force generation was substantially reduced by fasudil or Y27632, an effect even more enhanced in the absence of caveolin-1 signaling. Overall, these results indicate that caveolin-1 is a critical player in enhanced ASM contractility with airway inflammation.
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Infante, Jeffrey R., Chiorean, E. Gabriela , Bendell, Johanna C. , Molina, Julian R. , Tibes, Raoul , Ramanathan, Ramesh K., Lewandowski, Karen, Lacouture, Mario E. , Langmuir, Virginia K., Lee, Hank, Kroll, Stew, Burris, Howard A. , Infante, Jon , Weiss, Glen J. , Borad, Mitesh J. , Jones, Suzanne Fields , Infante, Jon

Mayo Clinic

Clinical Cancer Research | March 18, 2011 | Volume: 17 | Issue: 9 | Pages: 2997-3004

10.1158/1078-0432.ccr-10-3425 | PMID 21415214 Get It

Abstract Purpose: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors. Experimental Design: TH-302 was administered intravenously over 30 to 60 minutes in two regimens: three times weekly dosing followed by 1 week off (arm A) and every 3-week dosing (arm B). Results: Fifty-seven patients enrolled (arm A: N = 37 and arm B: N = 20). The TH-302 dose was escalated from 7.5 to 670 mg/m2 in arm A and from 670 to 940 mg/m2 in arm B. The most common adverse events were nausea, skin rash, fatigue, and vomiting. Hematologic toxicity was mild and limited. Grade 3 skin and mucosal toxicities were dose limiting at 670 mg/m2 in arm A; the MTD was 575 mg/m2. In arm B, grade 3 fatigue and grade 3 vaginitis/proctitis were dose limiting at 940 mg/m2; the MTD was 670 mg/m2. Plasma concentrations of TH-302 and the active metabolite Br-IPM (brominated version of isophosphoramide mustard) increased proportionally with dose. Two partial responses were noted in patients with metastatic small cell lung cancer (SCLC) and melanoma in arm A at 480 and 670 mg/m2. Stable disease was observed in arms A and B in 18 and 9 patients, respectively. Conclusions: The MTD of TH-302 was 575 mg/m2 weekly and 670 mg/m2 every 3 weeks. Skin and mucosal toxicities were DLTs. On the basis of responses in metastatic melanoma and SCLC, further investigations in these indications were initiated. Clin Cancer Res; 17(9); 2997–3004. ©2011 AACR.
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Robert, Nicholas J. , Brufsky, Adam , Bondarenko, Igor , Lipatov, Oleg , Perez, Edith A. , Zhou, Xian , Phan, S. , O’Shaughnessy, Joyce , Dièras, Véronique , Glaspy, John A. , Yardley, Denise Aysel , Chan, Stephen Y.T. , Brufsky, Adam M

Mayo Clinic

Journal of Clinical Oncology | March 8, 2011 | Volume: 29 | Issue: 10 | Pages: 1252-1260

10.1200/jco.2010.28.0982 | PMID 21383283 Get It

Purpose This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2–negative metastatic breast cancer. Patients and Methods Patients were randomly assigned in 2:1 ratio to chemotherapy plus BV or chemotherapy plus placebo. Before random assignment, investigators chose capecitabine (Cape; 2,000 mg/m 2 for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m 2 , docetaxel 75 or 100 mg/m 2 ), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, or fluorouracil/doxorubicin/cyclophosphamide]) chemotherapy administered every 3 weeks. BV or placebo was administered at 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), 1-year survival rate, objective response rate, duration of objective response, and safety. Two independently powered cohorts defined by the choice of chemotherapy (Cape patients or pooled Tax/Anthra patients) were analyzed in parallel. Results RIBBON-1 (Regimens in Bevacizumab for Breast Oncology) enrolled 1,237 patients (Cape cohort, n = 615; Tax/Anthra cohort, n = 622). Median PFS was longer for each BV combination (Cape cohort: increased from 5.7 months to 8.6 months; hazard ratio [HR], 0.69; 95% CI, 0.56 to 0.84; log-rank P < .001; and Tax/Anthra cohort: increased from 8.0 months to 9.2 months; HR, 0.64; 95% CI, 0.52 to 0.80; log-rank P < .001). No statistically significant differences in OS between the placebo- and BV-containing arms were observed. Safety was consistent with results of prior BV trials. Conclusion The combination of BV with Cape, Tax, or Anthra improves clinical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a safety profile comparable to prior phase III studies.
Pediatric Obesity and Self-Reported Health Behavior Information
Chen, Laura P. , Jenkins, Sarah M. , Beebe, Timothy J. , Ytterberg, Karen L., Ziegenfuss, Jeanette Y.

Mayo Clinic

Clinical Pediatrics | March 1, 2011 | Volume: 50 | Issue: 9 | Pages: 872-875

10.1177/0009922810397335 | PMID 21357199 Get It

Abstract 2662: Pharmacokinetics, metabolism and tissue distribution of the nitric oxide-donating prodrug JS-K following administration in liposomes
Buhrow, Sarah A. , Walden, Chad A., Jia, Lee , Davis, Myrtle, Keefer, Larry K., Barazi, Heba, Ames, Matthew M. , Reid, Joel M. , Davis, Myrtle

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2662-2662

10.1158/1538-7445.am10-2662 Get It

Abstract The diazeniumdiolate O2-(2,4-dinitrophenyl)-1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2diolate (JS-K, NSC 724771) is a nitric oxide (NO)-donating prodrug that was designed to release NO upon reaction with glutathione-S-transferase which is overexpressed in some tumors. We demonstrated that JS-K reacts with nucleophiles in biological fluids and has an extremely short half-life in mice. The purpose of the study was to test the hypothesis that liposomal encapsulation improves the in vivo half-life, tissue distribution and acute toxicity profile of JS-K. We investigated the pharmacokinetics of [3H]JS-K in CD mice administered the drug in DMSO or DMPC (dimyristoylphosphatidylcholine) liposomes (20:1 molar ratio of DMPC: JS-K) and in tumor-bearing athymic nu/nu NCr mice administered the radiolabeled drug in DMPC liposomes. The terminal elimination half-life of total radioactivity (2 hours) was similar for both formulations. We did not detect [3H]JS-K in any plasma or red blood cell samples from mice administered 6 mg/kg JS-K in DMSO and only trace amounts of [3H]JS-K were detected in samples collected at the earliest time-points from mice administered 6 mg/kg JS-K in DMPC liposomes. Small amounts of radioactivity, presumably associated with JS-K metabolites, were detected at the solvent front of HPLC chromatograms. Very little radioactivity and no JS-K was detected in tumor samples. Finally, we developed an LC/MS/MS assay to investigate formation of JS-K metabolites in biological samples and used that method to measure concentrations of JS-K and its metabolites in plasma, red blood cells, liver tissue and tumor tissue collected from tumor-bearing mice administered 3 mg/kg or 6 mg/kg JS-K in DMPC liposomes. We confirmed extremely rapid in vivo degradation of JS-K in the systemic circulation following intravenous administration and rapid formation of several expected metabolites including high concentrations of the glutathione conjugate of the dinitrophenol moiety and piperazine. Supported by NCI Contract NO1-CM-52206. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2662.
Abstract 2607: Endoxifen pharmacokinetics and bioavailability of in female rats and dogs
Buhrow, Sarah A. , Schweikart, Karen, Noker, Patricia E., Davis, Myrtle, Collins, Jerry M. , Ames, Matthew M. , Reid, Joel M. , Safgren, Stephanie L. , Jia, Lee , Davis, Myrtle, Goetz, Matthew P.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2607-2607

10.1158/1538-7445.am10-2607 Get It

Abstract Endoxifen (END), the active metabolite of tamoxifen (TAM), is currently being developed as a drug for the treatment of estrogen receptor positive breast cancer based on recent in vitro and clinical data demonstrating that TAM drug effect is substantially related to circulating plasma concentrations of END, a secondary metabolite produced by human CYP2D6 metabolism. Women with deficient CYP2D6 metabolism have lower END concentrations and a higher risk of breast cancer recurrence. We characterized the pharmacokinetics and oral bioavailability of END in female rats and dogs. We further compared END exposure following equivalent doses of END and TAM. Rats were administered 2 mg/kg i.v. END, 20 − 200 mg/kg oral END or 80 mg/kg oral TAM. Fasted dogs were administered 0.5 mg/kg i.v. END, 15 − 100 mg/kg oral END or 30 mg/kg oral TAM. Plasma END concentrations were also measured in rats or dogs after oral dosing once per day for 4 consecutive days. Plasma samples were analyzed using a validated reverse-phase HPLC method with fluorescence detection. In the single-dose administration study, terminal elimination half-life and plasma clearance values in rats given 2 mg/kg i.v. END were 6.3 h and 2.4 L/h/kg, respectively. Plasma concentrations above 0.1 µM and 1 µM END were achieved with 20 mg/kg and 200 mg/kg doses, respectively, and those concentrations were maintained for longer than 24 h. Oral absorption of END was linear over the range of 20 − 140 mg/kg with a bioavailability greater than 67%. END exposure in rats following 80 mg/kg oral END was 100-fold greater than END exposure following 80-mg/kg oral TAM. Following 0.5 mg/kg i.v. END to dogs, terminal elimination half-life and plasma clearance values were 9.2 h and 0.4 L/h/kg, respectively. Plasma concentrations above 1 µM and 10 µM were achieved with the 15 mg/kg dose and 100 mg/kg, respectively, and those concentrations were maintained for longer than 24 h. Absorption was linear over the range of 15 − 100 mg/kg with a bioavailability greater than 50%. END exposure in dogs following 30 mg/kg oral END was 10-fold greater than END exposure following 30-mg/kg oral TAM. In the repeated-dose administration study, the day 4 END peak plasma concentration in rats increased from 1 to 9 µM as the daily END dose was increased from 20 to 200 mg/kg. The day 4 END peak plasma concentration in dogs exceeded 20 µM and plasma concentrations remained above 2 µM for 24 hours following 4 daily doses of 30 mg/kg END. Based on these data, we conclude that END has high oral bioavailability; high concentrations may be maintained after repeated dosing in dogs and rats; and substantially higher END concentrations are achievable following an oral dose of END in comparison to a similar dose of TAM. Supported by NCI contract N01-CM-52206. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2607.